Voyager Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
75 Hayden Ave, Lexington, Massachusetts,...Phone Number
(857) 259-5340Website
www.voyagertherapeutics.comRevenue
$34.5 MillionStock Symbol
VYGRIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
1
2
2
2
2
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager's wholly-owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson's disease, Huntington's disease, Alzheimer's disease, and other neurodegenerative diseases related to defective or excess aggregation of tau and alpha-synuclein proteins in the brain. Voyager Therapeutics is headquartered in Cambridge, Massachusetts.Explore more
Voyager Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Voyager Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Voyager Therapeutics had a recent Job posting/layoffs
Check out if Voyager Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Voyager Therapeutics
Earning: See what the market has to say on Voyager Therapeutics recently announced quarterly report
Product Launch: Get notified when Voyager Therapeutics launches new products
Funding: Get notified immidiatlly once Voyager Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Voyager Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Voyager Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Voyager Therapeutics
Compare insights from companies similar to Voyager Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Voyager Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Voyager Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Voyager Therapeutics.
Voyager Therapeutics financials insights
Gather financial insights about Voyager Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$70M
Voyager Therapeutics Tech Stack
A closer look at the technologies used by Voyager Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Medical Research, Pharmaceuticals
Voyager Therapeutics News & Media
Voyager Reports Second Quarter 2026 Financial and Operating Results
- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
- Data presented as Developing Topics poster at AAIC 2026 -Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer's Association International Conference (AAIC) taking place in London, July 12-15, 2026. The Developing Topics poster presentation will feature VY1706, Voyager’s investigational gene therapy targeting intracellular andVoyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Voyager Therapeutics
Sign Up For FreeTo access detailed company insights
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager's wholly-owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson's disease, Huntington's disease, Alzheimer's disease, a... Read More
